Next Article in Journal
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug
Previous Article in Journal
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective

Article Versions Notes

Pharmaceutics 2024, 16(3), 389;
Action Date Notes Link
article xml file uploaded 12 March 2024 12:34 CET Original file -
article xml uploaded. 12 March 2024 12:34 CET Update
article pdf uploaded. 12 March 2024 12:34 CET Version of Record
article html file updated 12 March 2024 12:35 CET Original file
Back to TopTop